Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, has designed the helical metal nanostructures to mediate the manipulation of the chirality of drug molecules.
Scientists from Hong Kong Baptist University (HKBU) have developed a novel technique that can produce pure therapeutic drugs without the associated side effects.
The approach, which uses a nanostructure fabrication device, can manipulate the chirality of drug molecules by controlling the direction a substrate is rotated within the device, thus eliminating the possible side effects that can arise when people take drugs containing molecules with the incorrect chirality.
Published in the renowned international scientific journal Nature Chemistry, the research findings pave the way towards the mass production of purer, cheaper and safer drugs that can be made in a scalable and more environmentally-friendly way.
Control of molecular chirality improves drug safety
Many chemical molecules have two configurations, or chiral versions, that are mirror images of each other. While sharing the same molecular formula, the two chiral versions have different arrangements of their constituent atoms in space. The two versions of the molecules are characterised by left-handed and right-handed chiral configurations like human hands. Molecules with “left-handed” and “right-handed” chirality can have totally different biochemical effects.
More than half of the therapeutic drugs are made up of equal amounts of left-handed and right-handed chiral molecules, commonly known as “racemates”; one can cure specific diseases, but the other may have adverse effects. Separating and producing molecules with only the chiral arrangement (known as a single enantiomer) responsible for the therapeutic effects can help to produce drugs with improved safety and efficacy.
Macro-scale control of molecular chirality
In general, molecules have an extremely small size ranging from one-millionth to one hundred-thousandth of the diameter of a human hair. It is therefore extremely challenging to selectively produce one of the two chiral molecule versions using “macro-scale” control (i.e. the dimensional scale that can be seen using the naked eye and operated by hand). To produce single-enantiomer drugs, chemists have overwhelmingly used molecules called “chiral ligands” to effectively control the molecular chirality of drugs in the laboratory or industry at the molecular scale, a process called asymmetric synthesis. However, the existing technologies for producing single-enantiomer drugs are composed of complicated procedures, which are expensive and environmentally-unfriendly.
Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, and his research team devised a novel approach to manipulating molecular chirality through macro-scale control in collaboration with Sichuan University, Guangxi Medical University and the Southern University of Science and Technology. It involves mediating the manipulation with helical metal nanostructures (i.e. metal nanohelices) that are in the shape of a helical spring, and they have a characteristic size of one-thousandth of the diameter of a human hair.
Direction of rotation determines molecular chirality
The research team fabricated the metal nanohelices using a nanofabrication technique called glancing angle deposition (GLAD). Silver and copper were deposited onto a supporting substrate that was rotated clockwise and counterclockwise to fabricate the right-handed and left-handed metal nanohelices, respectively.
The research team then used ultraviolet light to induce a chemical reaction. This caused 2-anthracenecarboxylic acid (AC) molecules adsorbing on the metal nanohelices to undergo the chemical reaction and form chiral molecular products, which are similar to some chiral drugs. When AC was attached to the surface of the right-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “right-handed” chiral molecular products. By the same token, when AC was adsorbed on the surface of the left-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “left-handed” chiral molecular products. In other words, the chirality of the molecular product can be reliably determined by the chirality of the metal nanohelices, which is controlled by the direction of substrate rotation.
The research demonstrates that controlling the direction of substrate rotation at a macroscopic level can conveniently manipulate molecular chirality. This is an unprecedented application of the macro-scale method (through the control of the rotation direction of a 4-inch substrate holder) to manipulate chirality at the molecular-scale (chiral molecular products in the range of one-billionth of a metre).
Green approach to reducing drug side effects
“Our success in manipulating molecular chirality through macroscopic engineering allows the convenient synthesis of drugs in single-enantiomer forms with only left- or right-handedness. Hence, it will help get rid of the adverse, sometimes fatal, side effects of many therapeutic drugs,” said Dr Huang.
The use of chiral ligands in the conventional method of asymmetric synthesis is inevitable, and it may cause pollution to enter the environment. In contrast, in this novel approach the metal nanohelices can be used repeatedly to produce single-enantiomer drugs without the use of chiral ligands. As a result, it paves the way towards the mass production of affordable therapeutic drugs that are made in a scalable manner with recyclable materials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pure therapeutic drug production
- How psychedelic DMT promotes the production of new brain cellson November 8, 2020 at 4:26 pm
Robust new research, published in the journal Translational Psychiatry, is reporting on several years of animal studies showing how a psychedelic drug called dimethyltryptamine (DMT) can promote brain ...
- Central nervous system stimulants and sport practiceon November 8, 2020 at 11:38 am
Some are prescription drugs, such as Ephedra alkaloids, and there are issues regarding their appropriate therapeutic use ... metabolic rate, and urine production. High doses can cause anxiety, ...
- ACROBiosystems and the Fight Against COVID-19on October 23, 2020 at 10:17 am
ACROBiosystems is dedicated to accelerating the process of target therapeutic drug development from the ... of our Spike ECD protein product, the production of Biotinylated Spike Protein ...
- CBD Tincture: Top 5 Brands & Buyer’s Guideon October 23, 2020 at 5:30 am
leaving behind the pure cannabis oil. Supercritical CO2 extraction is considered the gold standard for CBD tincture production and produces the highest quality CBD oil. CO2 is an organic solvent ...
- Sihuan Pharmaceutical's Gabapentin Capsules was Granted Drug Production Approval, the Third Company Obtained Approval in Chinaon October 21, 2020 at 7:45 pm
Sihuan Pharmaceutical is the third company that obtained production approval ... administration, good drug tolerance, minimal toxicity and side effects and excellent therapeutic effect.
Go deeper with Google Headlines on:
Pure therapeutic drug production
Go deeper with Bing News on:
- Antidepressant drug fluvoxamine may prevent some serious complications of COVID-19on November 12, 2020 at 3:54 pm
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found ...
- Medicine: State could be affordable drug makeron November 12, 2020 at 3:03 pm
As the leader of Washington #insulin4all and a board member of Health Care for All Washington, I am working with our legislators to introduce a bill that will also allow our state to create its own ...
- Chinese 'cartels' quietly operating in Mexico, aiding US drug crisison November 12, 2020 at 2:50 pm
From nondescript buildings in the industrial nucleus of Wuhan, across wavy seas to dusty tented super laboratories in the heart of Mexico, and then across the jagged southwest border and dispersed ...
- UConn, DIANT Pharma licenses continuous manufacturing nanoparticle systemon November 12, 2020 at 9:53 am
The University of Connecticut recently licensed their groundbreaking continuous manufacturing technology for pharmaceutical nanoparticles in support of commercialization to DIANT Pharma Inc. The ...
- How Maryland Smith Is Helping the FDA Think About Drug Manufacturing and Riskon November 12, 2020 at 8:40 am
COLLEGE PARK, Md., Nov. 12, 2020 /PRNewswire/ -- Pandemic-era disruptions underscored a troubling reality in the pharmaceutical industry – an ...